RET protein inhibitor - Eli Lilly and Company
Alternative Names: RET inhibitor IILatest Information Update: 19 Feb 2023
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 02 Feb 2023 Phase-I clinical trials in Cancer in USA (Eli Lilly and Company pipeline, before February 2023)